Send to

Choose Destination
See comment in PubMed Commons below
Dermatol Ther. 2013 Jul-Aug;26(4):354-63. doi: 10.1111/dth.12076.

Treatment of dermatologic connective tissue disease and autoimmune blistering disorders in pregnancy.

Author information

Division of Dermatology, Philadelphia Veteran's Affairs Medical Center, Philadelphia, Pennsylvania 19104, USA.


Autoimmune skin disease occurs in pregnancy, and treatment is often required to control both maternal disease and fetal outcomes. Here we present the available safety data in pregnancy and lactation for medications used to treat autoimmune skin diseases, including cutaneous lupus erythematosus, dermatomyositis, morphea and systemic sclerosis, pemphigus vulgaris, pemphigus foliaceus, and pemphigoid gestationis. A PubMed search of the English-language literature using keywords, "pregnancy" "rheumatic disease," and "connective tissue disease" was performed. Relevant articles found in the search and references were included. Reasonable evidence supports the careful and cautious use of topical steroids, topical calcineurin inhibitors, systemic corticosteroids, hydroxychloroquine, and azathioprine in pregnancy. Case reports or clinical experience suggest intravenous immunoglobulin, dapsone, phototherapy, rituximab, and plasmapheresis may be safe. Several treatment options exist for autoimmune skin disease in pregnancy and lactation, and should be considered when treating these patients.


autoimmune skin disease; blistering disease; blistering disorders; cutaneous lupus erythematosus; dermatomyositis; lactation; morphea; pemphigoid gestationis; pemphigus foliaceus; pemphigus vulgaris; pregnancy; rheumatic skin disease

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center